ORCA Research Selected as Scientific Highlight at ESMO IO 2024

Amsterdam, Netherlands – December 2024

ORCA Therapeutics B.V., a Dutch biopharmaceutical company pioneering innovative oncolytic neo-adjuvant immunotherapies for cancer treatment, today announced that its groundbreaking research presentation by Professor Tanja de Gruijl at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO IO) 2024 has been selected as a scientific highlight of the conference by the Society for Immunotherapy of Cancer (SITC).

https://www.sitcancer.org/blogs/thomas-martin/2024/12/16/esmo-io-meeting-2024-dec-79

The presentation, which detailed further clinical insights into ORCA-010’s mechanism of action and its effects on the tumor microenvironment, garnered significant attention from the international oncology community. The prestigious ESMO IO Congress, held from December 11-13, 2024, showcases the latest advances in immuno-oncology and brings together leading researchers and clinicians from around the world. The selection as a scientific highlight represents exceptional recognition in a field marked by rapid innovation and breakthrough developments in antibody technologies.

“We are honored to receive this distinguished recognition from ESMO IO and the SITC,” said Dr. Wenliang Dong, Chief Executive Officer at ORCA Therapeutics. “The selection of Professor de Gruijl’s presentation as a scientific highlight underscores the innovative potential of ORCA-010 in cancer treatment. This recognition validates our approach to oncolytic immunotherapy and reflects our team’s dedication to developing breakthrough therapies for cancer patients.”

About ORCA-010

ORCA-010 is a state-of-the-art oncolytic adenovirus therapy designed for enhanced tumor killing capabilities, while modifying the tumor microenvironment and inducing anti-tumor immune responses. Our Phase I/IIA trial in treatment-naïve, early-stage prostate cancer patients demonstrate that ORCA-010 can induce long-term immunological activation of the tumor microenvironment and induce systemic anti-tumor immune responses, supporting ORCA-010’s continued investigation as a potential treatment approach for prostate cancer.

About ORCA Therapeutics BV

ORCA Therapeutics BV is a leader in potent neo-adjuvant immuno-oncology therapeutics, specializing in oncolytic viruses and innovative gene therapy approaches. The company is dedicated to translating cutting-edge scientific discoveries into effective therapeutic solutions, addressing unmet medical needs and improving patient outcomes globally.

For more information about our mission and ongoing projects, visit www.orca-therapeutics.com

Media Contact

Dr. Wenliang Dong, Ph.D., MBA
CEO, ORCA Therapeutics BV
Email: info@orca-therapeutics.com
Website: www.orca-therapeutics.com